Catch up on eczema advancements throughout the year, including news on contact dermatitis, chronic hand eczema, and more.
Kaitlyn Bader, Assistant Managing Editor
Advertisement
Kaitlyn Bader is the assistant managing editor of Dermatology Times® and joined the MJH Life Sciences team in June 2022. She oversees the content production of Dermatology Times, from digital and print to videos and podcasts, as well as live coverage of dermatology conferences. Prior to health care news, Kaitlyn worked in digital marketing. She enjoys cooking, reading, and tending to her houseplants.
You can reach her at [email protected].
Articles by Kaitlyn Bader, Assistant Managing Editor
Catch up on the latest news on prurigo nodularis advancements in 2024.
Dermavant’s sNDA for tapinarof cream 1% for AD is still under review with the FDA.
In case you missed it, this week we had news about phase 2 initiation of EVO756 for chronic inducible urticaria, IBI363's Fast Track Designation for advanced melanoma, Arcutis' enrollment of the last patient in ARQ-255 trial for alopecia areata, and more.
The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.
This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
How Emerging Androgenetic Alopecia Therapies Target DHT at the Scalp Level
2
Tildrakizumab Partially Reverses Epigenetic Aging in Psoriasis, Pilot Study Shows
3
Field-Directed Therapy Favored for Actinic Keratosis Management
4
Diet Linked to Improved Chronic Idiopathic Urticaria Control
5